» Articles » PMID: 32228309

Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of The...

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic that is wreaking havoc on the health and economy of much of human civilization. Electrophysiologists have been impacted personally and professionally by this global catastrophe. In this joint article from representatives of the Heart Rhythm Society, the American College of Cardiology, and the American Heart Association, we identify the potential risks of exposure to patients, allied healthcare staff, industry representatives, and hospital administrators. We also describe the impact of COVID-19 on cardiac arrhythmias and methods of triage based on acuity and patient comorbidities. We provide guidance for managing invasive and noninvasive electrophysiology procedures, clinic visits, and cardiac device interrogations. In addition, we discuss resource conservation and the role of telemedicine in remote patient care along with management strategies for affected patients.

Citing Articles

Initial experience, safety, and feasibility using remote access or onsite technical support for complex ablation procedures: results of the REMOTE study.

Heeger C, Vogler J, Eitel C, Feher M, Popescu S, Kirstein B Eur Heart J Digit Health. 2024; 5(3):356-362.

PMID: 38774365 PMC: 11104456. DOI: 10.1093/ehjdh/ztae013.


The clinical use of remote parameter testing during cardiac implantable electronic devices implantation procedures: a single center, randomized, open-label, non-inferiority trial.

Xiong S, Qin S, Tong L, Long Y, Luo Y, Feng Q Front Cardiovasc Med. 2024; 11:1364940.

PMID: 38586175 PMC: 10995217. DOI: 10.3389/fcvm.2024.1364940.


COVID-19 and cardiovascular complications: updates of emergency medicine.

Zhao J, Xie Y, Meng Z, Liu C, Wu Y, Zhao F Emerg Crit Care Med. 2024; 3(3):104-114.

PMID: 38314258 PMC: 10836842. DOI: 10.1097/ec9.0000000000000095.


Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease.

Hu C Nat Prod Bioprospect. 2024; 14(1):12.

PMID: 38282092 PMC: 10822835. DOI: 10.1007/s13659-024-00432-4.


Clinical and financial outcomes of hospitalizations for cardiac device infection during the COVID-19 pandemic in the US.

Ascandar N, Chervu N, Bakhtiyar S, Cho N, Kim S, Orellana M PLoS One. 2023; 18(9):e0291774.

PMID: 37729193 PMC: 10511080. DOI: 10.1371/journal.pone.0291774.


References
1.
Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W . Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004; 484(1):41-8. DOI: 10.1016/j.ejphar.2003.11.003. View

2.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

3.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

4.
Haeusler I, Chan X, Guerin P, White N . The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med. 2018; 16(1):200. PMC: 6220451. DOI: 10.1186/s12916-018-1188-2. View

5.
Bai Y, Yao L, Wei T, Tian F, Jin D, Chen L . Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020; 323(14):1406-1407. PMC: 7042844. DOI: 10.1001/jama.2020.2565. View